WO2022097117 - ANTIBODY DRUG CONJUGATES
National phase entry:
Publication Number
WO/2022/097117
Publication Date
12.05.2022
International Application No.
PCT/IB2021/060356
International Filing Date
09.11.2021
Title **
[English]
ANTIBODY DRUG CONJUGATES
[French]
CONJUGUÉS ANTICORPS-MÉDICAMENT
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
1-1, Doshomachi 4-Chome, Chuo-ku, Osaka-shi
Osaka, 541-0045, JP
Inventors
XU, He
c/o Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, Massachusetts 02139, US
LEE, Hong Myung
c/o Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, Massachusetts 02139, US
ARENDT, Christopher
c/o Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, Massachusetts 02139, US
Priority Data
63/111,478
09.11.2020
US
63/232,935
13.08.2021
US
63/250,358
30.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3200 | |
| EPO | Filing, Examination | 26319 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 640 | |
| USA | Filing, Examination | 11760 |
Total: 42513 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in a subject in need thereof.[French]
La présente invention concerne des conjugués anticorps-médicament comprenant des modulateurs de STING. L'invention concerne également des compositions comprenant lesdits conjugués anticorps-médicament. Les composés et les compositions sont utiles pour stimuler une réponse immunitaire chez un sujet dont l'état le nécessite.